BI 836858 Dose Escalation in Refractory or Relapsed Acute Myeloid Leukemia

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Boehringer Ingelheim
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01690624
First received: September 13, 2012
Last updated: September 3, 2014
Last verified: September 2014

September 13, 2012
September 3, 2014
September 2012
October 2015   (final data collection date for primary outcome measure)
Determination of the maximum tolerated dose of BI 836858, based on dose limiting toxicities [ Time Frame: up to 4 weeks ] [ Designated as safety issue: No ]
Determination of the maximum tolerated dose of BI 836858, based on dose limiting toxicities in a 3+3 design [ Time Frame: up to 8 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01690624 on ClinicalTrials.gov Archive Site
  • Change from baseline in percentage of myeloid blasts in the bone marrow [ Time Frame: up to 22 months ] [ Designated as safety issue: No ]
  • Change from baseline in blood counts (hemoglobin, platelets, neutrophils) [ Time Frame: up to 22 months ] [ Designated as safety issue: No ]
  • Best overall response rate according to International Working Group (IWG) criteria [ Time Frame: up to 22 months ] [ Designated as safety issue: No ]
  • Progression free survival [ Time Frame: up to 22 months ] [ Designated as safety issue: No ]
  • Time to treatment failure [ Time Frame: up to 22 months ] [ Designated as safety issue: No ]
  • Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: up to 22 months ] [ Designated as safety issue: Yes ]
  • Intensity of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: up to 22 months ] [ Designated as safety issue: Yes ]
  • Occurrence of drug related dose limiting toxicities throughout the study [ Time Frame: up to 22 months ] [ Designated as safety issue: No ]
  • Maximum measured plasma concentration (Cmax) [ Time Frame: up to 168 hours ] [ Designated as safety issue: No ]
  • Time from dosing to the maximum plasma concentration (tmax) [ Time Frame: up to 168 hours ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve over the time interval of one week (AUC0-168) [ Time Frame: up to 168 hours ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve over the time interval of one treatment cycle (AUC0-tz) [ Time Frame: up to 336 hours ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve over the time interval from zero extrapolated to infinity (AUC0-infinity) [ Time Frame: up to 168 hours ] [ Designated as safety issue: No ]
  • Terminal half-life (t1/2) [ Time Frame: up to 168 hours ] [ Designated as safety issue: No ]
  • Mean residence time after intravenous infusion (MRT) [ Time Frame: up to 168 hours ] [ Designated as safety issue: No ]
  • Total plasma clearance (CL) [ Time Frame: up to 168 hours ] [ Designated as safety issue: No ]
  • Apparent volume of distribution during the terminal phase (Vz) [ Time Frame: up to 168 hours ] [ Designated as safety issue: No ]
  • Volume of distribution after intravenous infusion at steady state (Vss) [ Time Frame: up to 168 hours ] [ Designated as safety issue: No ]
  • Change from baseline in percentage of myeloid blasts in the bone marrow [ Time Frame: up to 22 months ] [ Designated as safety issue: No ]
  • Change from baseline in blood counts (hemoglobin, platelets, neutrophils) [ Time Frame: up to 22 months ] [ Designated as safety issue: No ]
  • Best overall response rate according to International Working Group (IWG) criteria [ Time Frame: up to 22 months ] [ Designated as safety issue: No ]
  • Progression free survival [ Time Frame: up to 22 months ] [ Designated as safety issue: No ]
  • Time to treatment failure [ Time Frame: up to 22 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
BI 836858 Dose Escalation in Refractory or Relapsed Acute Myeloid Leukemia
A Phase I, Open Cohort Dose Escalation Trial With BI 836858 in Patients With Refractory or Relapsed Acute Myeloid Leukemia.

Patients with acute myeloid leukemia who experience a relapse after at least one prior regimen may be enrolled in this trial. The trial will examine whether monotherapy with BI 836858 is safe and tolerable at escalating dose levels.

Not Provided
Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Leukemia, Myeloid, Acute
Drug: BI 836858
Monotherapy with BI 836858 administered as intravenous infusion
Experimental: Patients with relapsed or refractoryAML
Patients with acute myeloid leukemia who have relapsed after 1 prior treatment.
Intervention: Drug: BI 836858
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
36
October 2015
October 2015   (final data collection date for primary outcome measure)

Inclusion criteria:

  1. Diagnosis of relapsed or refractory AML with at least one prior treatment for acute myeloid leukemia.
  2. Expression of CD33 on more than 30% of bone marrow blasts.
  3. Eastern Cooperative Oncology Group Performance Status 0, 1 or 2
  4. Age 18 years or older
  5. Written informed consent which is consistent with International Conference on Harmonization ¿ Good Clinical Practice (ICH-GCP) guidelines and local legislation.

Exclusion criteria:

  1. Patients with acute promyelocytic leukemia according to WHO definition.
  2. Patients with > 5.000 leukocytes/µl in the peripheral blood
  3. Anti-leukemia therapy within two weeks before first treatment with BI 836858, 4 weeks for biologics
  4. Allogeneic stem cell transplantation within the last 3 months or with evidence of graft versus host disease
  5. Patients who are candidates for allogeneic stem cell transplantation.
  6. Second malignancy currently requiring active therapy.
  7. Symptomatic central nervous system involvement
  8. Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (ULN), or AST or ALT greater than 5 times the ULN for those with Gilbert syndrome.
  9. Prothrombin time (PT) >1.5 x ULN for subjects not on therapeutic vitamin K antagonists (phenprocoumon, warfarin)
  10. Bilirubin greater than 1.5 mg/dl (>26 µmol/L) unless elevation is thought to be due to hepatic infiltration by AML, Gilbert syndrome, or hemolysis.
  11. Serum creatinine greater than 2.0 mg/dl
  12. Known human immunodeficiency virus (HIV) infection or active hepatitis B virus or hepatitis C virus infection.
  13. Concomitant intercurrent illness, or any condition which in the opinion of the Investigator, would compromise safe participation in the study, e.g. active severe infection, unstable angina pectoris, new onset of exacerbation of a cardiac arrhythmia
  14. Psychiatric illness or social situation that would limit compliance with trial requirements
  15. Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug
  16. Female patients of childbearing potential who are sexually active and unwilling to use a medically acceptable method of contraception during the trial and for 6 months after the last administration of BI 836858
  17. Male patients with partners of childbearing potential who are unwilling to use condoms in combination with a second effective method of contraception during the trial and for 6 months after the last administration of BI 836858
  18. Pregnant or nursing female patients
  19. Treatment with another investigational agent under the following conditions:

    1. Within two weeks (4 weeks for biologics) of first administration of BI 836858; or
    2. Patient has persistent toxicities from prior anti-leukemic therapies which are determined to be relevant by the Investigator.
    3. Concomitant treatment with another investigational agent while participating in this trial.
  20. Prior treatment with a CD33 antibody
  21. Patient unable or unwilling to comply with the protocol.
Both
18 Years and older
No
Contact: Boehringer Ingelheim Call Center 1-800-243-0127 clintriage.rdg@boehringer-ingelheim.com
United States
 
NCT01690624
1315.1
Not Provided
Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP